**New Oral Treatment Shows Promise for Relapsing Multiple Sclerosis**
**Dimethyl fumarate reduces disease activity and progression**
**WEB Neurology University Hospital Duesseldorf Duesseldorf Germany - Cited by 382**
A new oral treatment called dimethyl fumarate has been shown to reduce disease activity and progression in patients with relapsing multiple sclerosis (MS). The study, published in the journal Neurology, found that the treatment was well-tolerated and had a favorable safety profile.
Dimethyl fumarate is a fumaric acid ester that has been used for centuries to treat psoriasis. In recent years, it has been investigated as a potential treatment for MS, a chronic autoimmune disease that affects the central nervous system.
The study included 257 patients with relapsing MS who were randomized to receive either dimethyl fumarate or placebo. The patients were followed for two years, and the results showed that the dimethyl fumarate group had a significant reduction in the number of relapses, as well as a decrease in the rate of disease progression.
The study authors concluded that dimethyl fumarate is a "promising novel oral therapeutic option" for patients with relapsing MS.
Comments